Welcome to our dedicated page for NOVONIX SEC filings (Ticker: NVNXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NOVONIX Limited filings document foreign-issuer reports furnished on Form 6-K, with exhibits drawn from ASX announcements and corporate notices. The record includes disclosures on annual general meeting presentations and voting results, material-event updates, material agreements, operating and financial results, and governance matters tied to the company's battery materials business.
Capital-structure filings cover applications for quotation of ordinary fully paid securities, securities issued from option exercises or convertible-security conversions, performance rights, and director interest notices. These filings also record shareholder voting matters and formal updates relevant to NOVONIX's ADR and foreign-issuer reporting framework.
NOVONIX Limited has reported the lapse of 139,547 NVXAD performance rights. These rights ceased on February 2, 2026 because the conditions attached to them were not met or had become incapable of being satisfied. No consideration was paid in connection with this cessation.
After this change, the company reports 859,902,420 NVX ordinary fully paid shares on issue. It also has 17,388,628 remaining NVXAD performance rights, 14,016,667 NVXAA options, 1,008,567 NVXAB share rights and 45,221,586 NVXAL convertible notes on issue.
NOVONIX LIMITED is arranging quotation on ASX for 127,021 new ordinary fully paid shares, issued on 30 January 2026 after conversion of performance rights under an employee incentive scheme. These shares are issued for non-cash consideration valued at AUD 0.39 per share.
The new shares form part of the existing NVX ordinary share class and will rank equally with all other quoted ordinary shares from their issue date. After this quotation, the company reports 859,902,420 NVX ordinary shares on issue, along with several unquoted classes including performance rights, options, share rights and convertible notes.
NOVONIX Limited filed a quarterly activities and cash flow update showing continued investment in battery materials alongside higher funding. Operating activities used $9.7M in cash for the quarter, while capital expenditure reached $13.4M, mainly on the Riverside anode materials facility.
Financing inflows from unsecured convertible debentures totaled $49.4M this quarter, lifting cash and equivalents to $81.3M as of 31 December 2025, or an estimated 8.4 quarters of funding at the current burn rate. The company completed its full $100M Yorkville debenture program in 2025.
Commercially, NOVONIX advanced its anode and cathode platforms, delivering over 100 synthetic graphite samples to 15 customers and 10 cathode samples to seven OEMs and Tier‑1 battery makers, and launched a UHPC Calibration Module. Offsetting this, Stellantis terminated its large offtake agreement, while NOVONIX remains focused on Panasonic, PowerCo and other prospects amid supportive U.S. trade actions on Chinese graphite.
Novonix Limited filed a Form 6-K as a foreign private issuer for December 2025. The filing mainly forwards an exhibit, Appendix 2A, which is an application for quotation of securities dated December 18, 2025. The report is signed by the Chief Financial Officer, Robert Long.
Novonix Limited has reported a change in its board of directors. The company submitted a report to U.S. regulators highlighting an attached announcement from the Australian Securities Exchange.
The exhibit notes the appointment of Mike O'Kronley to the Board of Directors, dated December 15, 2025. This update formally records the new board role for investors who follow Novonix through U.S. markets.